Living Well after Breast Cancer
To evaluate the telephone-delivered weight loss intervention compared to usual care, on its ability to promote and maintain weight loss, and to improve body composition, physical activity, dietary intake, clinical biomarkers of metabolic health (glucose, lipids, HbA1c, insulin, leptin, adiponectin, C Reactive Protein), genomic and DNA methylation-based biomarkers, blood pressure and patient-reported outcomes (quality of life, body image, fatigue, menopausal symptoms).
A randomised controlled trial of an 12-month telephone-delivered weight loss intervention for overweight and obese women with breast cancer. Participants will be allocated 1:1 to intervention or usual care groups, using permuted block randomisation. The primary outcome is weight loss (expressed as a percent of initial body weight), assessed at 6-months (short-term), 12-months (end-of-intervention) and 18-months (maintenance post-intervention). The trial is registered with the Australian and New Zealand Clinical Trials Register.
Data collection on the final project particpant completed 2nd September 2016. A huge milestone.
Publications:
Results:
